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Introduction:Breast cancer is the commonest cancer among females in 
both developed and developing countries [1]. 
 
In the field of breast 
cancer, in most of the articles, young woman is defined to be below the 
age of 35 or the age of 40 [2].
 
The results of the National Population-
Based Cancer Registry Program in Egypt, showed that, among females, 
the proportion of breast cancer was 32 % of all female cancers [3]. In 
study applied in Gharbia over 10 years (1999-2008), the result was that 
the majority of breast cancer cases during the study period were 
diagnosed among women aged 40 – 49 years (31.8%) and among 
women aged 50–59 years (29.8%) [4] one decade younger than the 
corresponding age in western countries. 
Patients and methods:This was a retrospective study in which the 
records of patients presenting with breast carcinoma who were admitted 
to the unit of Surgical Oncology and to the Clinical Oncology and 
Nuclear Medicine department, Alexandria Main University Hospital 
from January 2000 to December 2009 were collected. 
Results: There was higher incidence of hormone positive tumors in 
older patients with a significant difference statistically (p 0.001 for ER 
receptors and p 0.010 for PR receptors). there is a significant reduction 
in the disease-free survival (p <0.001) and overall survival (p <0.001) 
in patient who developed breast cancer before 40 years. 
Conclusion: Hormone-positive tumors are more common in patients 
older than 40 years which may indicate a better prognosis in this age 
group.Younger age at diagnosis of breast cancer is an adverse 
prognostic factor for relapse of the disease even when effective 
adjuvant therapy is given. This based on disease free survival and 
overall survival are worse in young age group. 
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Introduction:- 
Breast cancer is the commonest cancer among females in both developed and developing countries [1]. 
 
In the field 
of breast cancer, in most of the articles, young woman is defined to be below the age of 35 or the age of 40 [2].
 
The 
results of the National Population-Based Cancer Registry Program in Egypt, showed that, among females, the 
proportion of breast cancer was 32 % of all female cancers [3].
 
In study applied in Gharbia over 10 years (1999-
2008), the result was that the majority of breast cancer cases during the study period were diagnosed among women 
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aged 40 – 49 years (31.8%) and among women aged 50–59 years (29.8%) [4], one decade younger than the 
corresponding age in western countries. Breast cancer in Egypt has been reported to be biologically more aggressive 
disease than that in Western countries with predominance of premenopausal patients with late presentation in 
advanced stages [5,6]. The incidence of breast cancer among young females in Africa and Middle East reaches up to 
20% of cases. The aetiology of this high incidence may be attributed to genetic or environmental factors [7]. Young 
patients diagnosed with breast cancer usually have a worse prognosis than older patients [8].
 
Young women 
diagnosed with breast cancer experience the same problems experienced by their older counterparts like abdominal 
pain, hair loss and bone aches in addition to the problems of infertility, early menopause, changed body image and 
sexuality [9]. Age is considered as an independent prognostic factor. Breast cancer occurring young women tends to 
have an aggressive behaviour such as HER2 over-expression and triple negative subtypes and is more likely to be 
diagnosed in a late stage. This may explain the poor outcome of younger patients as regarding the locoregional 
recurrence and the overall survival [10, 11]. Breast conserving therapy in women younger than 35 years is 
associated with higher risk of local recurrence than older patients [12].
 
 
Patients and methods:
 
This was a retrospective study in which the records of patients presenting with breast carcinoma who were admitted 
to the unit of Surgical Oncology and to the Clinical Oncology and Nuclear Medicine department, Alexandria Main 
University Hospital from January 2000 to December 2009 were collected. All available records and blocks for these 
patients were retrieved. 
 
In this study, we divided all patients in to two groups: 
1. Group I: patients presenting with Breast carcinoma at age ≤ 40 years. 
2. Group II: patients presenting with Breast carcinoma at age >40 years. 
 
Exclusion criteria for this study included: 
1. Male breast cancer  
2. Patients with pathology rather than carcinoma 
3. Patients without data about pathological assessment and patients without follow-up records. 
 
Data were fed to the computer and analyzed using IBM SPSS software package version 20.0. (Armonk, NY: IBM 
Corp). The Kolmogorov- Smirnov, Shapiro and D’agstino tests were used to verify the normality of distribution of 
variables, Comparisons between groups for categorical variables were assessed using Chi-square test (Fisher or 
Monte Carlo). Mann Whitney test was used to compare between two groups for abnormally distributed 
quantitative variables. Kaplan-Meier Survival curve was used. Significance of the obtained results was judged at 
the 5% level. 
 
Results:-  
The study was done on 3820 cases diagnosed with breast cancer in the period between January 2000 to December 
2009 with follow up period of 5 years. 
  
Some of the reports were deficient in some parts. 
 
Patients younger than 40 years at the time of diagnosis represents 15.6% of all cases (fig. 1) 
 
There was a higher incidence of cribriform nsitu carcinoma in younger patients. More breast conserving surgeries 
and oncoplastic procedure were done for young patients. Mastectomy was done in most of the cases. (table 1) 
Table 2 shows the different parameters studied and comparing both age groups in relation to these parameters. There 
was higher incidence of hormone positive tumors in older patients with a significant difference statistically (p 0.001 
for ER receptors and p 0.010 for PR receptors) 
 
Table 3,4 and figure 2 show that there is a significant reduction in the disease-free survival (p <0.001) and overall 
survival (p <0.001) in patient who developed breast cancer at age younger than 40 years. 
 
By the end of the study (5 years),31 patients in the young group died from the disease and 16 patients in the old 
group died from the disease with statistical significance (p <0.001) 
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Discussion:- 
Breast cancer in females before the age of 40 years is uncommon and reaches nearly 7% of all cases at diagnosis in 
United States. According to many epidemiological studies in the last twenty years, this group of patients has raised 
special interest for being associated with poorer prognosis when compared to cases diagnosed over the age of 40. 
The majority of these studies were done in Europe and United States [13,14].  
 
Since breast cancer is considered a potentially curable disease, a more aggressive approach may be needed if it is 
confirmed that young patients with breast cancer have increased incidence of relapse and low survival [15]. 
 
In the United States, a large retrospective cohort study of 243,012 breast cancer patients diagnosed between 1988 
and 2003, showed that only 6.4% were younger than 40 years old [16].
 
While in our study, we found that patients 
diagnosed with breast cancer account for 15.6% of cases. This disparity is attributed to differences in population 
structure with more young population in Egypt; median age of females’ population in Egypt is 24 years at 2016 
while in USA median age is 38 years at 2016. Also, Egyptian female life expectancy, while increasing greatly in the 
last 50 years from approximately 49 years in 1960 to 74 years for 2016, is still currently lower than the USA 2016 
estimate of 82 years. 
 
In the current study, no significant association with age groups as regard the presence of lymphovascular invasion, 
although there was a higher incidence of presence of lymphovascular invasion in the young group, a finding similar 
to that reported in many published series [17]. On contrast Song et al [18] showed LVI was significantly associated 
with young patients aged ≤ 40 years, also Cancello et al [19] concluded that there were higher percentages of tumors 
with LVI in young patients. 
 
In our study; there was no statistically significant difference in the distribution of TNM stage between two age 
groups. These results were consistent with many studies [20, 21].
 
In contrast, several studies concluded that the 
percentage of patients diagnosed with more advanced stages was higher in the young patients than the older patients 
[22, 23]. While LIN et al [15]
 
concluded that younger patients (< 50 years) were significantly associated with higher 
frequencies of stage I than older patients (≥ 50 years). 
 
In the current study, there were more ER and PR negative cases in the younger age group than in the older age group 
with statistical significance. This matches with the results of many studies that showed the same results [19, 22].  
In the current work, there was no significant difference in HER-2 positivity between 2 age groups, which is 
consistent with other published works analysing series of young patients [24, 25].
 
While many studies concluded 
that HER2 positivity is more frequent in young patients which inversely affect the prognosis of young breast cancer 
patients [19, 22 and 26]. 
 
In our study, the 5 years disease free survival was less in young patients with higher relapse rate with statistical 
significance. Also, the overall survival was less in the young age group. This is not explained by the primary size of 
the tumor or the lymph node status as they were more or less the same in both groups with no statistical significance.  
These results are consistent with results from many published data which reported that Being 40 or younger is an 
independent risk factor for relapse in operable breast cancer patients [17, 22 and 27]. 
 
Conclusion:- 
1. Hormone-positive tumors are more common in patients older than 40 years which may indicate a better 
prognosis in this age group. 
2. Younger age at diagnosis of breast cancer is an adverse prognostic factor for relapse of the disease even when 
effective adjuvant therapy is given. This based on disease free survival and overall survival are worse in young 
age group. 
 
Table 1:-Comparison between the two age groups according to different parameters 
 Age (years) Test of sig. p 
 <40 ≥40 
Multiplicity in MAMO (n = 122) (n = 539)   
Single 109(89.3%) 491(91.1%) χ2= 0.398 0.820 
Multifocal 9(7.4%) 32(5.9%) 
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Multicentric 4(3.3%) 16(3%) 
NEOADJ Type (n = 389) (n = 1877)   
No 367(94.3%) 1757(93.6%) χ2= 0.298  
0.585 Yes 22(5.7%) 120(6.4%) 
Response to NEOADJ (n = 10) (n = 50)   
Partial response 6(60%) 27(54%) χ2= 1.214 0.622 
Poor response 4(40%) 16(32%) 
Complete path response 0(0%) 7(14%) 
Type of surgery (n = 490) (n = 2421)   
No 9(1.8%) 21(0.9%) χ2= 15.696 0.004* 
BCT 41(8.4%) 114(4.7%) 
Oncoplastic 0(0%) 1(0.04%) 
Mastectomy 438(89.4%) 2278(94.1%) 
Mastectomy & Recon 1(0.2%) 2(0.1%) 
Qudrantectomy 1(0.2%) 5(0.2) 
T size (n = 297) (n = 1581)   
Median (Min. – Max.) 4 (0.1 – 18) 3.50 (0 – 17) U=221920.5 0.130 
Path Types (n = 438) (n = 2192)   
IDC 420(95.9%) 2051(93.6%) χ2=3.468 0.063 
ILC 3(0.7%) 56(2.6%) χ2=5.820* 0.016* 
DCI 2(0.5%) 9(0.4%) χ2=0.019 1.000 
Mixed 5(1.1%) 51(2.3%) χ2=2.460 0.117 
Medullary 5(1.1%) 12(0.5%) χ2=2.006 0.183 
Paget dis+ IDC 0(0%) 5(0.2%) χ2=1.001 0.598 
Mucinous 1(0.2%) 6(0.3%) χ2=0.028 1.000 
LCIS 0(0%) 1(0.05%) χ2=0.200 1.000 
Cribriform 2(0.5%) 0(0%) χ2=10.017* 0.028* 
Paget dis+ dcis 0(0%) 1(0.05%) χ2=0.200 1.000 
Tumor grade (n = 317) (n = 1528)   
0 5(1.6%) 32(2.1%) χ2= 2.349 0.672 
1 10(3.2%) 59(3.9%) 
2 255(80.4%) 1249(81.7%) 
3 47(14.8%) 187(12.2%) 
4 0(0%) 1(0.1%) 
LV invasion (n = 180) (n = 841)   
Yes 104(57.8%) 469(55.8%) χ2= 0.243 0.622 
No 76(42.2%) 372(44.2%) 
2, p:  2 and p values for Chi square test for comparing between the two groups  
U, p: U and p values for Mann Whitney test for comparing between the two groups : Statistically significant at p ≤ 
0.05   
 
Table 2:-Comparison between the two age groups according to different parameters 
 Age (years) Test of sig. p 
 <40 ≥40 
Pathological T (n = 298) (n = 1503)   
0 0(0%) 1(0.1%) χ2= 3.679 0.469 
1 44(14.8%) 281(18.7%) 
2 178(59.7%) 870(57.9%) 
3 62(20.8%) 275(18.3%) 
4 14(4.7%) 76(5.1%) 
Median (Min. – Max.) 2(1 – 4) 2(0 – 4) U=213583.0 0.155 
Pathological N (n = 337) (n = 1577)   
0 91(27%) 475(30.1%) χ2= 3.241 0.356 
1 90(26.7%) 429(27.2%) 
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2 98(29.1%) 456(28.9%) 
3 58(17.2%) 217(13.8%) 
Median (Min. – Max.) 1(0 – 3) 1(0 – 3) U= 251672.5 0.113 
Stage (n = 296) (n = 1451)   
0 0(0%) 1(0.1%) χ2= 4.502 0.356 
1 18(6.1%) 103(7.1%) 
2 116(39.2%) 638(44.0%) 
3 158(53.4%) 697(48.0%) 
4 4(1.4%) 12(0.8%) 
Stage Level (n = 296) (n = 1450)   
Early stage 122(41.2%) 673(46.4%) χ2= 3.436 0.179 
Locally advanced 170(57.4%) 766(52.8%) 
Metastatic 4(1.4%) 11(0.8%) 
ER score (n = 309) (n = 1351)   
Negative 70(22.7%) 200(14.8%) χ2= 11.378* 0.001* 
Positive 239(77.3%) 1151(85.2%) 
PR test (n = 309) (n = 1411)   
Negative 79(25.6%) 269(19.1%) χ2= 6.640* 0.010* 
Positive 230(74.4%) 1142(80.9%) 
HER2 (n = 90) (n = 373)   
Negative 16(17.8%) 60(16.1%) χ2= 0.151 0.697 
Positive 74(82.2%) 313(83.9%) 
KI (n = 48) (n = 171)   
Low 26(54.2%) 100(58.5%) χ2= 0.285 0.593 
High 22(45.8%) 71(41.5%) 
2, p:  2 and p values for Chi square test for comparing between the two groups  
U, p: U and p values for Mann Whitney test for comparing between the two groups 
*: Statistically significant at p ≤ 0.05   
 
Table 3:-Comparison between the two age groups according to different parameters 
 Age (years) Test of sig. p 
 <40 ≥40 
Luminal subtypes (n = 58) (n = 205)   
A 14(24.1%) 71(34.6%) χ2= 4.590 0.332 
B Her2 -ve 13(22.4%) 49(23.9%) 
B Her2 +ve 13(22.4%) 44(21.5%) 
Her2 Enriched 5(8.6%) 15(7.3%) 
Triple -ve 13(22.4%) 26(12.7%) 
Hormonal status tumor (n = 326) (n = 1487)   
Negative 54(16.6%) 143(9.6%) χ2= 13.326* <0.001* 
Positive 272(83.4%) 1344(90.4%) 
Disease free survival event (n = 281) (n = 1231)   
Free 156(55.5%) 851(69.1%) χ2= 19.064* <0.001* 
Mets 125(44.5%) 380(30.9%) 
5yr dis free months (n = 261) (n = 1147)   
Median (Min. – Max.) 48 (0 – 60) 48 (0 – 60) U=133373.5* 0.004* 
Overall survival event (n = 284) (n = 1234)   
Alive 274(96.5%) 1230(99.7%) χ2= 25.823* <0.001* 
Died 10(3.5%) 4(0.3%) 
5yr OS months (n = 259) (n = 1141)   
Median (Min. – Max.) 60 (6 – 60) 60 (12 – 60) U= 141503.5 0.211 
2, p:  2 and p values for Chi square test for comparing between the two groups  
U, p: U and p values for Mann Whitney test for comparing between the two groups 
*: Statistically significant at p ≤ 0.05   
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Table 4:-Kaplan-Meier survival curve for overall survival  
Age groups Mean (months) % End of study Log rank 
 p 
<40 58.8 94.9 27.672
*
 <0.001
*
 
≥40 59.9 99.5 
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